onc Videos

Videos

Sponsored

Videos

Targeting HER2 in Metastatic Colorectal Cancer: Emerging and Future Options

08/04/2023

In this symposium, experts discuss the molecular basis for HER2-targeted therapy for patients with HER2-positive colorectal cancer, the diagnostic approach for HER2-amplified metastatic colorectal cancer, and the ongoing journey of precision...

In this symposium, experts...

08/04/2023

Oncology

Bradley Monk, MD, University of Arizona School of Medicine

Videos

Mirvetuximab Soravtansine for Folate Receptor-Alpha High, Platinum-Resistant Ovarian Cancer

08/02/2023

Featuring Bradley J. Monk, MD

Bradley Monk, MD, discusses the results from the phase 3 MIRASOL trial and shares insights about mirvetuximab soravtansine for folate receptor-alpha high, platinum-resistant ovarian cancer.

Bradley Monk, MD, discusses the...

08/02/2023

Oncology

Maximilian Kloft, MD, Maastricht University

Videos

Relationship Between Tumor Infiltrating Immune Cells And Tumor Draining Lymph Nodes Among Patients With Esophageal Cancer

08/01/2023

Featuring Maximilian Kloft, MD

Featuring Maximilian Kloft, MD ...

At the 2023 World Congress on Gastrointestinal Cancers, Maximilian Kloft, MD, presented results from a study relating the tumor infiltrating lymphocytes and the tumor-draining lymph nodes in esophageal cancer.

At the 2023 World Congress on...

08/01/2023

Oncology

Kristen Ciombor, MD, Vanderbilt-Ingram Cancer Center

Videos

Checkpoint Inhibition for Patients With Colorectal Cancer and High Microsatellite Instability

08/01/2023

Featuring Kristen Ciombor, MD

At the 2023 World Congress on Gastrointestinal Cancers, Kristen Ciombor, MD, discussed the opportunities for checkpoint inhibition among patients with colorectal cancer and high microsatellite instability.

At the 2023 World Congress on...

08/01/2023

Oncology

Philip Philip, MD, Wayne State University

Videos

Next-Generation Sequencing for All Patients With Pancreatic Ductal Adenocarcinoma

08/01/2023

Featuring Philip Philip, MD

At the 2023 World Congress on Gastrointestinal Cancers, Philip Philip, MD, argued for doing next-generation sequencing for all patients with pancreatic ductal adenocarcinoma.

At the 2023 World Congress on...

08/01/2023

Oncology

Yu Sunakawa, MD, St. Marianna University School of Medicine

Videos

Modified FOLFOXIRI Plus Cetuximab as the First-Line Treatment for Patients With RAS Wild-Type Metastatic Colorectal Cancer

07/28/2023

Featuring Yu Sunakawa, MD

At the 2023 ESMO World Congress on Gastrointestinal Cancers, Yu Sunakawa, MD, presented updated survival data from the phase 2 DEEPER trial, evaluating modified(m)-FOLFOXIRI plus cetuximab vs m-FOLFOXIRI plus bevacizumab among patients with...

At the 2023 ESMO World Congress...

07/28/2023

Oncology

Federica Marmorino, MD, University of Pisa

Videos

Effect of Gut Microbiome Composition on Atezolizumab Efficacy Among Patients With Colorectal Cancer

07/28/2023

Featuring Federica Marmorino, MD

Featuring Federica Marmorino, MD ...

At the 2023 World Congress on Gastrointestinal Cancers, Federica Marmorino, MD, discusses the effect the gut microbiome composition may have on the efficacy of checkpoint inhibitors like atezolizumab for colorectal cancer.

At the 2023 World Congress on...

07/28/2023

Oncology

Kathleen Moore, MD, Stephenson Cancer Center

Videos

Mirvetuximab Soravtansine Improved Overall Survival for Patients With Folate Receptor Alpha-High Platinum-Resistant Ovarian Cancer

07/27/2023

At the 2023 ASCO Annual Meeting, Kathleen Moore, MD, shares results from the MIRASOL trial, evaluating mirvetuximab soravtansine among patients with folate recetor alpha-high platinum-resistant ovarian cancer.

At the 2023 ASCO Annual Meeting,...

07/27/2023

Oncology

Videos

Epcoritamab Plus Rituximab and Lenalidomide Regimen Demonstrates High Response Rates Among Patients With High-Risk Follicular Lymphoma

07/19/2023

Featuring Reid Merryman, MD

At the 2023 ASCO meeting, Reid Merryman, MD, shares data assessing the efficacy and safety of epcoritamab plus rituximab and lenalidomide among patients with R/R FL.

At the 2023 ASCO meeting, Reid...

07/19/2023

Oncology

Eileen O'Reilly, MD, Memorial Sloan Kettering Cancer Center

Videos

Current Standards and Emerging Options for Pancreatic Cancer

07/18/2023

Featuring Eileen O'Reilly, MD

At the 2023 World Congress on Gastrointestinal Cancers, Eileen O’Reilly, MD, discusses the existing standards and upcoming options for the treatment of pancreatic cancer.

At the 2023 World Congress on...

07/18/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology